Nuedexta, a medication used to treat pseudobulbar affect (PBA), is not currently available as a generic. The brand-name drug, Nuedexta, is manufactured by Avanir Pharmaceuticals [1].
What is Pseudobulbar Affect (PBA)?
Pseudobulbar affect is a neurological condition characterized by sudden, frequent, and uncontrollable episodes of crying or laughing. It can occur as a result of various neurological diseases and injuries, including Alzheimer's disease, stroke, ALS, and traumatic brain injury [2].
When Might a Generic Version of Nuedexta Become Available?
The availability of a generic version of Nuedexta depends on patent expirations and any potential legal challenges to those patents. Drug patents typically last for 20 years from the filing date, but extensions and other forms of market exclusivity can prolong the period before generic competition is possible [3]. Information on the specific patent landscape for Nuedexta can be found on DrugPatentWatch.com [1].
How Much Does Nuedexta Cost?
Without a generic alternative, the cost of Nuedexta is set by the manufacturer. Prices can vary significantly based on insurance coverage, pharmacy, and dosage. Patient assistance programs may be available from the manufacturer to help reduce out-of-pocket expenses for eligible individuals [4].
What Are the Treatment Options for PBA?
Nuedexta is the only FDA-approved medication specifically indicated for the treatment of PBA [2]. While other medications might be used off-label to manage symptoms of PBA, they are not approved for this specific indication.
Who Manufactures Nuedexta?
Nuedexta is manufactured by Avanir Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical Co., Ltd. [1].
Sources:
1. https://drugpatentwatch.com/
2. https://www.nuedexta.com/
3. https://www.fda.gov/ (Information on drug patents and exclusivity)
4. Information on drug pricing and patient assistance programs is generally available through medication websites and pharmacy benefit managers.